Literature DB >> 7963584

Tolerance to a self-peptide from the third hypervariable region of HLA DRB1*0401 in rheumatoid arthritis patients and normal subjects.

S Salvat1, I Auger, L Rochelle, A Begovich, L Geburher, A Sette, J Roudier.   

Abstract

The third hypervariable region (HV3) of HLA-DRB1*0401 helps the development of severe rheumatoid arthritis by an unknown mechanism. To test whether the third hypervariable region of HLA-DRB1*0401 may shape the T cell repertoire, we studied proliferative responses to peptides encompassing the third hypervariable region of seven HLA-DRB1 alleles in normal subjects and patients with rheumatoid arthritis. We found that, in general, there is no tolerance to peptides from the third hypervariable region of self-HLA-DRB1 alleles. However, a peptide from the third hypervariable region of DRB1*0401 (DRB1*0401 HV3 peptide) is tolerated in people who express HLA-DRB1*0401. Indeed, PBMCs from people who express DRB1*0401 do not proliferate to DRB1*0401 HV3 peptide. Conversely, people who express DRB1*1501 respond to DRB1*0401 HV3 peptide. Finally, people who express both DRB1*0401 (nonresponder haplotype) and DRB1*1501 (high responder haplotype) do not respond to DRB1 HV3 peptide, thus demonstrating tolerance. Therefore, the third hypervariable region of HLA-DRB1*0401 shapes the T cell repertoire.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7963584

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  Interaction between HSP73 and HLA-DRB1*0401: implications for the development of rheumatoid arthritis.

Authors:  Isabelle Auger; Jean Roudier
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 2.  Molecular mechanisms involved in the association of HLA-DR4 and rheumatoid arthritis.

Authors:  I Auger; E Toussirot; J Roudier
Journal:  Immunol Res       Date:  1997-02       Impact factor: 2.829

3.  A function for the QKRAA amino acid motif: mediating binding of DnaJ to DnaK. Implications for the association of rheumatoid arthritis with HLA-DR4.

Authors:  I Auger; J Roudier
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

4.  H2-A polymorphism contributes to H2-Ebeta-mediated protection in collagen-induced arthritis.

Authors:  M A Gonzalez-Gay; E Zanelli; S D Khare; C J Krco; M M Griffiths; H S Luthra; C S David
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

5.  Absence of peripheral blood T cell responses to "shared epitope' containing peptides in recent onset rheumatoid arthritis.

Authors:  G J McColl; J Hammer; L C Harrison
Journal:  Ann Rheum Dis       Date:  1997-04       Impact factor: 19.103

6.  HLA-DRB1*0404 is strongly associated with anticalpastatin antibodies in rheumatoid arthritis.

Authors:  Isabelle Auger; Chantal Roudier; Sandrine Guis; Nathalie Balandraud; Jean Roudier
Journal:  Ann Rheum Dis       Date:  2007-02-26       Impact factor: 19.103

7.  Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment.

Authors:  Mattias Magnusson; Mikael Brisslert; Kiandoht Zendjanchi; Magnus Lindh; Maria I Bokarewa
Journal:  Rheumatology (Oxford)       Date:  2010-06-14       Impact factor: 7.580

8.  Heterogeneity of rheumatoid arthritis: from phenotypes to genotypes.

Authors:  C M Weyand; P A Klimiuk; J J Goronzy
Journal:  Springer Semin Immunopathol       Date:  1998

9.  Variable response to a candidate cancer vaccine antigen: MHC control of the antibody response in the rat to avian erythroblastosis virus (AEV)-encoded epithelial growth factor receptor but not AEV-encoded thyroid hormones receptor.

Authors:  N Nardi; N A Mitchison
Journal:  Mol Med       Date:  1995-07       Impact factor: 6.354

10.  Polymorphism of the MHC class II Eb gene determines the protection against collagen-induced arthritis.

Authors:  M A Gonzalez-Gay; E Zanelli; C J Krco; G H Nabozny; J Hanson; M M Griffiths; H S Luthra; C S David
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.